• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过可变形图像配准对胰腺癌进行立体定向体部放射治疗再照射后危及器官的剂量评估及胃肠道毒性预测。

Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration.

作者信息

Cao Yangsen, Zhu Xiaofei, Yu Chunshan, Jiang Lingong, Sun Yongjian, Guo Xueling, Zhang Huojun

机构信息

Department of Radiation Oncology, Changhai Hospital Affiliated to Naval Medical University, Shanghai, China.

出版信息

Front Oncol. 2023 Jan 30;12:1021058. doi: 10.3389/fonc.2022.1021058. eCollection 2022.

DOI:10.3389/fonc.2022.1021058
PMID:36793343
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9923872/
Abstract

PURPOSE

Re-irradiation of locally recurrent pancreatic cancer may be an optimal choice as a local ablative therapy. However, dose constraints of organs at risk (OARs) predictive of severe toxicity remain unknown. Therefore, we aim to calculate and identify accumulated dose distributions of OARs correlating with severe adverse effects and determine possible dose constraints regarding re-irradiation.

METHODS

Patients receiving two courses of stereotactic body radiation therapy (SBRT) for the same irradiated regions (the primary tumors) due to local recurrence were included. All doses of the first and second plans were recalculated to an equivalent dose of 2 Gy per fraction (EQD). Deformable image registration with the workflow "Dose Accumulation-Deformable" of the MIM System (version: 6.6.8) was performed for dose summations. Dose-volume parameters predictive of grade 2 or more toxicities were identified, and the receiver operating characteristic (ROC) curve was used to determine optimal thresholds of dose constraints.

RESULTS

Forty patients were included in the analysis. Only the of the stomach [hazard ratio (HR): 1.02 (95% CI:1.00-1.04), P = 0.035] and of the intestine [HR: 1.78 (95% CI: 1.00-3.18), P = 0.049] correlated with grade 2 or more gastrointestinal toxicity. Hence, the equation of probability of such toxicity was Additionally, the area under the ROC curve and threshold of dose constraints of of the stomach and of the intestine were 0.779 and 77.575 cc, 0.769 and 4.22 Gy (α/β = 3), respectively. The area under the ROC curve of the equation was 0.821.

CONCLUSION

The of the stomach and of the intestine may be vital parameters to predict grade 2 or more gastrointestinal toxicity, of which the threshold of dose constraints may be beneficial for the practice of re-irradiation of locally relapsed pancreatic cancer.

摘要

目的

对局部复发的胰腺癌进行再照射可能是一种局部消融治疗的最佳选择。然而,预测严重毒性的危及器官(OARs)的剂量限制尚不清楚。因此,我们旨在计算和识别与严重不良反应相关的OARs累积剂量分布,并确定再照射的可能剂量限制。

方法

纳入因局部复发在相同照射区域(原发肿瘤)接受两程立体定向体部放疗(SBRT)的患者。将第一和第二计划的所有剂量重新计算为每分次2 Gy的等效剂量(EQD)。使用MIM系统(版本:6.6.8)的“剂量累积-可变形”工作流程进行可变形图像配准以进行剂量求和。确定预测2级或更高级别毒性的剂量体积参数,并使用受试者操作特征(ROC)曲线确定剂量限制的最佳阈值。

结果

40例患者纳入分析。仅胃的[危险比(HR):1.02(95%CI:1.00 - 1.04),P = 0.035]和小肠的[HR:1.78(95%CI:1.00 - 3.18),P = 0.049]与2级或更高级别的胃肠道毒性相关。因此,这种毒性的概率方程为此外,胃的和小肠的的ROC曲线下面积和剂量限制阈值分别为0.779和77.575 cc、0.769和4.22 Gy(α/β = 3)。该方程的ROC曲线下面积为0.821。

结论

胃的和小肠的可能是预测2级或更高级别胃肠道毒性的重要参数,其剂量限制阈值可能有助于局部复发胰腺癌的再照射实践。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/59e0285b0772/fonc-12-1021058-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/49af938b1594/fonc-12-1021058-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/45f9064107ce/fonc-12-1021058-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/1d14e7bd5816/fonc-12-1021058-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/59e0285b0772/fonc-12-1021058-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/49af938b1594/fonc-12-1021058-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/45f9064107ce/fonc-12-1021058-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/1d14e7bd5816/fonc-12-1021058-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9853/9923872/59e0285b0772/fonc-12-1021058-g004.jpg

相似文献

1
Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration.通过可变形图像配准对胰腺癌进行立体定向体部放射治疗再照射后危及器官的剂量评估及胃肠道毒性预测。
Front Oncol. 2023 Jan 30;12:1021058. doi: 10.3389/fonc.2022.1021058. eCollection 2022.
2
The Dosimetric Analysis of Duodenal and Intestinal Toxicity After a Curative Dose Re-irradiation Using the Intensity-Modulated Radiotherapy for Abdominopelvic Lymph Node Lesions.使用调强放射治疗对腹盆腔淋巴结病变进行根治性剂量再照射后十二指肠和肠道毒性的剂量学分析。
Cureus. 2023 Dec 21;15(12):e50920. doi: 10.7759/cureus.50920. eCollection 2023 Dec.
3
Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases.立体定向体部放疗用于既往接受过立体定向体部放疗的胰腺癌靶区内复发的再照射:24例连续病例分析
Front Oncol. 2021 Nov 2;11:729490. doi: 10.3389/fonc.2021.729490. eCollection 2021.
4
Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose-escalation strategy.在胰腺癌屏息调强放疗中胃和肠道的分次剂量变化:对剂量递增策略的影响。
Med Phys. 2013 Feb;40(2):021701. doi: 10.1118/1.4773033.
5
A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome.前列腺内复发的高剂量率近距离放射治疗或立体定向体部放射治疗的前瞻性研究:毒性和长期临床结果
Front Oncol. 2022 Apr 5;12:861127. doi: 10.3389/fonc.2022.861127. eCollection 2022.
6
Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience.为前列腺癌复发患者进行立体定向体部放疗再程照射寻找安全的剂量体积限制:欧洲肿瘤研究所的经验。
Phys Med. 2021 Dec;92:62-68. doi: 10.1016/j.ejmp.2021.11.005. Epub 2021 Dec 3.
7
Re-irradiation in the thorax - An analysis of efficacy and safety based on accumulated EQD2 doses.胸部再放疗 - 基于累积 EQD2 剂量的疗效和安全性分析。
Radiother Oncol. 2020 Nov;152:56-62. doi: 10.1016/j.radonc.2020.07.033. Epub 2020 Jul 24.
8
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.多模态治疗后孤立性局部复发性胰腺癌行立体定向体部放射治疗的新治疗选择:来自两家机构的经验。
J Gastrointest Oncol. 2013 Dec;4(4):343-51. doi: 10.3978/j.issn.2078-6891.2013.044.
9
Re-Irradiation of Hepatocellular Carcinoma: Clinical Applicability of Deformable Image Registration.肝细胞癌的再照射:可变形图像配准的临床适用性
Yonsei Med J. 2016 Jan;57(1):41-9. doi: 10.3349/ymj.2016.57.1.41.
10
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar.局部晚期胰腺癌(LAPC)患者剂量递增立体定向体部放射治疗(SBRT)的剂量学可行性研究:是时候提高标准了。
Front Oncol. 2020 Dec 17;10:600940. doi: 10.3389/fonc.2020.600940. eCollection 2020.

引用本文的文献

1
In search of new stratification strategies: tissue proteomic profiling of papillary thyroid microcarcinoma in patients with localized disease and lateral neck metastases.探寻新的分层策略:局限性疾病伴侧颈部转移的甲状腺微小乳头状癌的组织蛋白质组分析。
J Cancer Res Clin Oncol. 2023 Dec;149(19):17405-17417. doi: 10.1007/s00432-023-05452-0. Epub 2023 Oct 20.

本文引用的文献

1
A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study.局部进展期不可切除的胰腺腺癌的非手术 COMBO- 治疗方法:一项前瞻性研究的初步结果。
Radiol Med. 2022 Feb;127(2):214-219. doi: 10.1007/s11547-021-01441-w. Epub 2022 Jan 15.
2
Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma.局部复发性胰腺腺癌立体定向体部放射治疗的疗效和安全性。
Clin Oncol (R Coll Radiol). 2022 Jun;34(6):386-394. doi: 10.1016/j.clon.2021.12.014. Epub 2021 Dec 31.
3
Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score).
采用新的预后模型(SCAD 评分)预测胰腺癌立体定向体部放射治疗后总生存。
Radiother Oncol. 2018 Nov;129(2):313-318. doi: 10.1016/j.radonc.2018.08.012. Epub 2018 Sep 11.
4
Review of thoracic reirradiation with stereotactic body radiation therapy: A focus on toxicity risks.胸段再放疗的立体定向体部放疗回顾:关注毒性风险。
Pract Radiat Oncol. 2018 Jul-Aug;8(4):251-265. doi: 10.1016/j.prro.2018.01.008.
5
Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database.立体定向体部放射治疗联合诱导或辅助化疗用于早期但医学上无法手术切除的胰腺癌:一项对前瞻性收集数据库的倾向评分匹配分析。
Cancer Manag Res. 2018 May 21;10:1295-1304. doi: 10.2147/CMAR.S163655. eCollection 2018.
6
Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer.立体定向体部放射治疗与化疗不同联合方案治疗局部晚期胰腺癌的前瞻性分析
Cancer Med. 2018 Jul;7(7):2913-2924. doi: 10.1002/cam4.1553. Epub 2018 May 17.
7
Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation.立体定向体部放射治疗用于既往接受过放疗的局部进展期和复发性胰腺癌
Front Oncol. 2018 Mar 7;8:52. doi: 10.3389/fonc.2018.00052. eCollection 2018.
8
Evaluation of Deformable Image Registration (DIR) Methods for Dose Accumulation in Nasopharyngeal Cancer Patients during Radiotherapy.鼻咽癌患者放疗期间剂量累积的可变形图像配准(DIR)方法评估
Radiol Oncol. 2017 Sep 15;51(4):438-446. doi: 10.1515/raon-2017-0033. eCollection 2017 Dec.
9
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
10
Deformable image registration applied to lung SBRT: Usefulness and limitations.可变形图像配准在肺部立体定向放疗中的应用:实用性与局限性
Phys Med. 2017 Dec;44:108-112. doi: 10.1016/j.ejmp.2017.09.121. Epub 2017 Sep 25.